FDA Approves Amgen And Allergan's KANJINTI ™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)
Approval Based on Totality of Evidence Demonstrating KANJINTI is Biosimilar to Herceptin
Third FDA Approval From Amgen's Biosimilars Portfolio
THOUSAND OAKS, Calif., June 13, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI™ (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzumab): for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
"The FDA approval of KANJINTI is an important milestone for our biosimilars portfolio, prov...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news
More News: Adenocarcinoma | Allergy | Breast Cancer | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Gastric (Stomach) Cancer | Gastroenterology | HER2 | Herceptin | Pharmaceuticals